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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, TaiwanBackground: The survival of children with malignant germ cell tumor (GCT) increased over the
past 2 decades with platinum-based chemotherapy. This report has three objectives: (1) com-
parison of PVB (cisplatin, vinblastine, and bleomycin) with JEB (carboplatin, etoposide, and
bleomycin) regimens; (2) treatment modality of vaginal GCT; and (3) management of stage I
testicular yolk sac tumor (YST) in boys under 2 years old.
Methods: From January 1, 1987 to December 31, 2010, 81 patients with malignant extracranial
GCT were treated. Two consecutive protocols, PVB followed by JEB, were used. Girls with
vaginal YST received minimal surgery and chemotherapy. Boys under 2 years old with Stage I
testicular YST received surgery with or without chemotherapy.
Results: As of June 30, 2012, the 10-year overall survival (OS) was 95  3% (standard error) and
the event-free survival (EFS) was 88  4%. With PVB, 35 patients had 10-year OS of 91  5% and
EFS of 89  5%. With JEB, 25 patients had 7-year OS of 96  5% and EFS of 96  5%. All five girls
with vaginal YST were cured with vagina-preserved strategy. In 32 boys age under 2 years old
with stage I YST, 16 with light chemotherapy were all in EFS, whereas two of 16 patients
without chemotherapy relapsed. After PVB, six patients developed nephrotoxicity and one
had pulmonary fibrosis.Pediatric HematologyeOncology, Mackay Memorial Hospital, 92, Section 2, Chung-San North Road,
tw (D.-C. Liang).
014.12.003
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302 J.-Y. Hou et alConclusion: Girls with vaginal YST who received minimal surgery and chemotherapy had excel-
lent prognosis and sexual organs were preservable. Light chemotherapy after surgery is a treat-
ment option for boys under 2 years old with stage I YST to decrease relapse rate. Both JEB and
PVB are effective. JEB resulted in more myelosuppression but otherwise less serious long-term
toxicity than PVB.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The treatment outcomes for children with malignant
extracranial germ cell tumor (MEGCT) have improved
markedly in the past 2 decades.1e3 This has been achieved
by the introduction of platinum-containing chemotherapy
regimen, effective surgical intervention, and better sup-
portive care.4,5 However, a degree of renal impairment or
deafness attributed to cisplatin has been reported.3,6 The
substitution of carboplatin for cisplatin, reduced dose of
bleomycin to avoid lung fibrosis, and administration of
etoposide comprised an effective treatment for MEGCT
with acceptable toxicities.2 To the best of our knowledge,
no comparison in treatment results and complications be-
tween PVB (cisplatin, vinblastine, and bleomycin) and JEB
(carboplatin, etoposide, and bleomycin) was reported. This
report has three objectives: (1) comparison PVB with JEB
regimens; (2) the treatment modality of vaginal germ cell
tumor (GCT); and (3) management of Stage I testicular yolk
sac tumor (YST) in boys younger than 2 years. First, we
analyzed all cases treated at our hospital and compared the
outcome and complications between two consecutive pro-
tocols, PVB and JEB regimens. Second, several previous
reports described successful treatment by radical surgery,
radiotherapy, and chemotherapy in girls with vaginal
GCT.7e9 The complications in survivors include loss of
reproductive function and/or long-term urological prob-
lems. We reported patients with vaginal GCT treated by
combination chemotherapy and minimal surgery to pre-
serve their sexual organs as far as possible. The literature
showed that patients under 2 years with Stage I GCT of the
testes treated with surgery alone had good survival rates
but still had relapses.2,10 In this study, we compared the
outcomes between surgery alone and with the addition of
light chemotherapy in boys younger than 2 years with Stage
I testicular YST.
2. Methods
2.1. Patients
From January 1, 1987 to December 31, 2010, 81 children 
15 years old with newly diagnosed MEGCT were treated
after written informed consent was obtained from guard-
ians. The subtypes included YST, dysgerminoma, malignant
teratoma, and embryonal carcinoma. Five patients having
immature teratoma with YST and greatly elevated serum
alpha-fetoprotein (AFP) levels were classified as malignantteratoma and treated with chemotherapy. The treatment
result of boys with Stage I testicular YST has been reported
in part,11 whereas more patients were included in this study
with longer follow-up.
2.2. Pretreatment evaluation
Clinical evaluation included complete blood cell count,
serum electrolytes, creatinine, bilirubin, alanine amino-
transferase, aspartate aminotransferase, alkaline phos-
phatase, albumin, phosphorus, uric acid, lactate
dehydrogenase, and tumor markers including serum AFP
and human chorionic gonadotropin. Increased AFP was
calculated as magnification of the average normal serum
level of children at various ages.12 Staging imaging evalu-
ation included chest radiography, computed tomography of
the brain, chest, and abdomen, long bone survey, and
technetium-99 bone scan.
2.3. Staging
Staging was based on St. Jude Children’s Research Hospital
Staging System for GCTs13 as follows: Stage Idcomplete
surgical resection with margin free from tumor, and nega-
tive tumor markers after 1 month postoperatively; Stage
IIdgross resection with microscopic residual disease,
negative tumor markers; Stage IIIdgross resection with
macroscopic residual disease,  tumor markers; and Stage
IVddistant metastases  tumor markers.
2.4. Surgery
Patients received complete surgical excision of the tumor if
no major morbidity was predicted; otherwise, biopsy was
performed. For those with vaginal YST, only a small biopsy
was performed prior to chemotherapy in an attempt to
preserve the organs. Those with residual tumors after
chemotherapy underwent second-look surgery. Boys
younger than 2 years old with Stage I testicular YST
received radical inguinal orchidectomy including high liga-
tion of the spermatic cord without retroperitoneal
lymphadenectomy.
2.5. Chemotherapy
Two consecutive protocols, PVB (from January 1987 to
December 1998) followed by JEB (after January 1999), were
used for patients with MEGCT. PVB consisted of bleomycin
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and cisplatin (90 mg/m2 on Day 3). Hydration for 6 hours
with mannitol and then cisplatin infusion with continuous
hydration for at least 24 hours after the end of chemo-
therapy were given. JEB consisted of etoposide (120 mg/
m2/d on Days 1e3), carboplatin (600 mg/m2 on Day 2), and
bleomycin (15 mg/m2 on Day 3). Chemotherapy was given
with 21-day intervals. For those in whom complete surgical
excision was attainable initially at diagnosis, two to four
courses of chemotherapy were given. For those with unre-
sectable disease, and four to six courses of chemotherapy
were given to decrease the tumor size to make tumors
resectable. Two additional courses of chemotherapy were
given following second-look surgery for patients with re-
sidual disease, whereas no further therapy was given for
those without residuals and with normalized AFP level (in
YST). Boys younger than 2 years with Stage I testicular YST
were stratified into two treatment groups after surgery,
with or without light chemotherapy, according to the de-
cision of the guardians. Those patients with chemotherapy
received either four courses of PVB or two courses of JEB
after January 1999. Chemotherapy dosage for infants
younger than 12 months was based on kilogram where 1 m2
of body surface area equaled a body weight of 30 kg.
2.6. Assessment of treatment response and toxicity
Patients who had elevated tumor markers at diagnosis
received further measurement weekly until normal values
were reached, then every 4e6 weeks for 2 years, every 3
months for 3 years, and every 6 months for further 2 years.
All image abnormalities were assessed by chest radiog-
raphy, abdominal ultrasonography, and/or computed to-
mography every 3 months. Nephrotoxicity was defined as a
doubling of baseline creatinine levels after chemotherapy.
Ototoxicity was evaluated by audiometry.
2.7. Statistical analysis
The duration of overall survival (OS) was defined as the
time from the start of treatment to death from any cause,
and event-free survival (EFS) from the start of treatment to
first progression, relapse, or death from any causes. Sur-
vival rates were estimated using the KaplaneMeier method.
Univariate analyses of prognostic factors were conducted
with two-sided log-rank test. The difference in the com-
plications between PVB and JEB was tested using Fisher’s
exact test. A statistically significant difference was defined
as p < 0.05. Survival rates were described as
mean  standard error.
3. Results
3.1. Patients’ characteristics
Overall, 81 patients (consisting of 46 boys and 35 girls) were
enrolled. The primary sites and their histologic diagnoses
are summarized in Table 1. They consisted of 39 Stage I, six
Stage II, 25 Stage III, and 11 Stage IV. The 22 patients with
primary extragonadal tumors included five vaginal, fivesacrococcygeal, seven retroperitoneal, four posterior
mediastineal, and one diaphragmatic tumors.14 The pre-
dominant histology was YST. Serum AFP levels were
elevated in all YST patients with a median level of 3301 ng/
mL (range, 64e232,340 ng/mL). Patients with Stages I or II
disease had lower AFP levels (510 ng/mL) than those with
Stages III and IV disease (1035 ng/mL). There were differ-
ences in neither AFP levels between gonadal (570 ng/mL)
and extragonadal (758 ng/mL) tumors, nor outcomes be-
tween survivors (602 ng/mL) and nonsurvivors (671 ng/mL).
Two patients with dysgerminoma had elevated human
chorionic gonadotropin levels (193 IU/L and 994 IU/L).
3.2. Overall outcome
The 10-year OS and EFS rates for all patients were 95  3%
(standard error) and 88  4%, respectively. The survival
probability is shown in Figure 1. Thirty-five patients treated
with PVB had 10-year OS rate of 91  5%, and 10-year EFS of
89  5%. The 7-year OS and EFS rates for 25 patients treated
with JEB were 96  5% and 96  5%, respectively. A total of
32 boys younger than 2 years had Stage I testicular YST.
After the surgery, nine of them received short-term PVB,
seven received short-term JEB, and 16 had observation
alone. Patients who received chemotherapy had 10-year OS
and EFS rates of 100%, whereas patients without chemo-
therapy had a 10-year OS rate of 100%, and a 10-year EFS of
88  8%.
3.3. Outcome according to clinical and biologic
factors
The outcomes based on the clinical and biologic features of
patients are shown in Table 2.
3.3.1. Stages I and II
Generally, the outcomes were good. Two boys younger than
2 years with Stage I testicular YST did not receive chemo-
therapy and had intrathoracic and intra-abdominal relapses
at 6 months and 18 months after orchiectomy, respectively.
They then received six courses of PVB and surgical resection
of the relapsed tumors. The patient with intra-abdominal
relapse that was complicated with adhesion ileus received
surgery.
3.3.2. Stages III and IV
Thirteen patients without any residual tumors had no
further surgery after chemotherapy. Ten patients with
Stage III disease who had residual tumors underwent a
second-look surgery after a median of five courses of
chemotherapy. Fibrosis was found in nine patients, and the
remaining patient with a viable malignant tumor received
further chemotherapy including an additional four courses
of JEB, three courses of cisplatin, vinblastine, and ifosfa-
mide, and one course of vincristine, cyclophosphamide,
and epidoxorubicin. One 1-year-old girl with Stage III ma-
lignant teratoma developed pulmonary fibrosis and pneu-
monia with respiratory failure after five courses of PVB and
died. Of 11 patients with Stage IV disease, second-look
surgery revealed eight complete fibrotic tissues and one
without any residual tumor. After a median of six courses of
Table 1 Tumor sites and histology in patients with malignant germ cell tumor.
Sites Histologic classification
Yolk sac tumor Malignant teratoma Dysgerminoma Embryonal carcinoma Total n (%)
Testis 42 2 44 (54)
Ovary 6 4 4 1 15 (19)
Vagina 5 5 (6)
Sacrococcyx 4 1 5 (6)
Retroperitoneum 5 2 7 (9)
Mediastinum 4 4 (5)
Diaphragm 1 1 (1)
Total n (%) 67 (83) 9 (11) 4 (5) 1 (1) 81
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remaining two patients, one dysgerminoma and the other
YST, died from progressive disease despite five courses of
PVB and radiotherapy. One 3-year-old girl with Stage IV YST
who had multiple relapsed tumors died despite 4 years of
chemotherapy.
3.3.3. Vaginal YST
Five patients’ diagnoses were made from minimal vaginal
wall biopsy, including three with lower pelvic YST with
extensive vaginal invasion and two with primary vaginal
YST. Three patients received a second-look biopsy after six
courses of chemotherapy and showed only fibrotic tissue.
Two patients without any residual tumor received no
further surgery after four courses of chemotherapy. One 2-
year-old girl had elevated AFP levels 2 months after six
courses of JEB without demonstrable tumors on computed
tomography. She received two further courses of JEB
because the AFP level reached 100 ng/mL. All five patients
were free of disease after 66e153 months.
3.3.4. Toxicity
Table 3 lists the complications. Nephrotoxicity was only
found in PVB. Loss of magnesium from urine and neu-
tropenia were similar in each regimen. Patients treated
with JEB developed higher rate of febrile neutropenia thanFigure 1 Overall survival (OS) and event-free survival (EFS)
of 35 patients treated with PVB (cisplatin, vinblastine, bleo-
mycin) and 25 patients treated with JEB (carboplatin, etopo-
side, bleomycin).those treated with PVB. Of the six patients treated with
PVB, hearing loss was found in one patient, pulmonary
fibrosis in two patients, cerebral and renal arterial throm-
bosis in one patient, and syndrome of inappropriate anti-
diuretic hormone secretion in two patients.4. Discussion
PVB for the treatment of GCT at Mackay Memorial Hospital,
Taipei, Taiwan, from 1987 to 1998 demonstrated a 91%
survival rate, which was at least comparable to the suc-
cessful study groups worldwide.1,2 Because the survival
rates had approached 90%, an optimized treatment proto-
col was aimed at minimizing the late effects such as
cisplatin-induced ototoxicity and renal impairment.3,15e18
In patients treated with PVB, six patients experienced
renal impairment (causing delay of chemotherapy), one
pulmonary fibrosis causing death, one syndrome of inap-
propriate antidiuretic hormone secretion, one hearing loss
after complete treatment, and one arterial thrombosis. The
United Kingdom Children’s Cancer Study Group (UKCCSG)
study showed that JEB, substitution of carboplatin for
cisplatin, greatly reduced the occurrence of both ototox-
icity and nephrotoxicity.2 Accordingly, we have used JEB
since 1999. The complications were reduced whereas the
frequency of febrile neutropenia increased, which was
similar to the results of the UKCCSG study.2 JEB was asso-
ciated with more myelotoxicity, but there was no septic
event in our patients. The JEB protocol was very effective
with acceptable toxicity. In this retrospective study, there
can be only historical comparison between PVB and JEB
without randomization.
Vaginal YST is a rare neoplasm, ranging from 3% to 8% of
GCT and develops almost exclusively in children younger
than 2 years. Therapy was historically based on the com-
bination of chemotherapy, radical surgery involving
extended hysterectomy, vaginectomy, and/or lymph node
dissection, and radiotherapy. However, the prognosis was
dismal.7 Survivors may lose their reproductive function
and/or suffer urological complications after extensive sur-
gery and radiotherapy. After the introduction of cisplatin-
based chemotherapy, the survival rate improved signifi-
cantly. The current survival rate at 2 years for vaginal
malignant GCT has been reported to be 90%.19e21 A con-
servative biopsy was performed instead of extensive sur-
gery to minimize lifelong side effects. In our study, three
Table 2 Patient characteristics and treatment outcome.
Category No. of patients 10-y EFS (SE) p 10-y OS (SE) p
Sex 0.87 0.39
Male 46 91 (5) 97 (3)
Female 35 90 (6) 93 (5)
Age (y) 0.41 0.46
<1 23 87 (7) 97 (4)
1e5 39 92 (4) 95 (4)
>5 19 85 (10) 91 (8)
Stage 0.19 0.11
I 39 92 (4) 97 (2)
II 6 83 (15) 83 (15)
III 25 93 (6) 97 (4)
IV 11 75 (15) 83 (13)
Sites 0.79 0.27
Gonadal 59 89 (4) 96 (3)
Extragonadal 22 91 (7) 91 (8)
Histology 0.11 0.08
Yolk sac tumor 67 94 (4) 98 (2)
Malignant teratoma 9 80 (13) 80 (13)
Dysgerminoma 4 60 (22) 80 (18)
Embryonal carcinoma 1 100 100
AFP level (ng/mL) 0.48 0.52
<150 16 88 (8) 94 (6)
150e670 20 96 (6) 96 (6)
670e2000 16 88 (8) 88 (8)
>2000 16 100 100
Chemotherapy 0.27 0.37
PVB 35 89 (5) 91 (5)
JEB 25 96 (5)* 96 (5)y
Stage I testes, <2 y old 0.15
Light chemotherapy 16 100 100
No chemotherapy 16 88 (8) 100
AFPZ alpha-fetoprotein; EFSZ event-free survival; JEBZ carboplatin, etoposide, bleomycin; OSZ overall survival; PVBZ cisplatin,
vinblastine, bleomycin.
* Seven-year EFS.
y Seven-year OS.
Treatment of extracranial germ cell tumor 305patients had residual mass shadow after six courses of
chemotherapy that were later proven to be fibrotic re-
siduals through biopsy. The other two children without any
residual tumors after chemotherapy did not require second-Table 3 Complications in PVB and JEB regimens.
Complication PVB, n (%) JEB, n (%)
Neutropenia 8 (23) 8 (32)
Febrile neutropenia 5 (3) 10 (40)
Nephrotoxicity 6 (17) 0 (0)
SIADH 2 (6) 0 (0)
Magnesium loss 4 (11) 1 (4)
Pulmonary fibrosis 1 (3) 0 (0)
Hearing loss 1 (3) 0 (0)
Cerebral and renal
artery thrombosis
1 (3) 0 (0)
JEBZ carboplatin, etoposide, bleomycin; PVBZ cisplatin,
vinblastine, bleomycin; SIADHZ syndrome of inappropriate
antidiuretic hormone secretion.look surgery. As all patients with vaginal YST responded
well to chemotherapy, extensive surgery and radiotherapy
were spared and long-term complications minimized. One
patient had undulant AFP elevation without demonstrable
tumors on a series of image studies and received two more
courses of JEB. She was free of disease 96 months after the
cessation of chemotherapy. Our findings of excellent results
confirm that initial biopsy alone followed by platinum-
containing chemotherapy and vaginal preservation in pa-
tients is the ideal approach for vaginal YST. In our study, all
patients with vaginal YST survived without evidence of
disease at follow-up of 66e153 months with intact vagina
and uterus.
For boys younger than 2 years with resected Stage I
testicular YST, the evolution and difference in the man-
agement modes, in the 1990s and at present, bring up two
strategiesdwait-and-see and light chemotherapy. Patients
with stage I GCTs of the testes have good survival rates with
surgery alone.10 To minimize the toxicities of chemo-
therapy and to keep high cure rates in < 2-year-old children
with completely resected Stage I testicular GCTs, a wait-
306 J.-Y. Hou et aland-see policy is generally followed.2,10,22e25 However,
10e25% of patients who received orchiectomy alone had a
later relapse. Even with rescue chemotherapy, some died.
Furthermore, the strict follow-up schedule required for
those with surgery alone may cause stress or result in
noncompliance.23,24 We initiated the treatment modality
that offered four courses of PVB from 1987 to 1998 and two
courses of JEB after 1999 in boys younger than 2 years with
Stage I resected testicular tumor. The courses of chemo-
therapy were decreased to reduce toxicity. There are
relatively few published reports of adjuvant chemotherapy
for children younger than 2 years with testicular GCT.25 We
aimed to decrease the relapse rates, diminish the cost, as
well as lessen the anxiety about the risk of relapse and the
inconvenience of scrupulous follow-up. In our study, all
children who received chemotherapy were event-free
without significant treatment-related toxicity at a median
follow-up of 126 months. One patient experienced febrile
neutropenia and required 5-day hospitalization. There was
no sepsis, nephrotoxicity, ototoxicity, hypomagnesemia, or
lung fibrosis in the chemotherapy group. Two children who
received orchiectomy alone relapsed, but they were alive
after surgical resection and adjuvant chemotherapy. Among
them, one patient had adhesion ileus 1 year later and un-
derwent surgery for intestinal lysis with anastomosis. Our
results suggest that PVB or JEB are similarly safe and
tolerable for Stage I YST of testis in children < 2 years old.
Light chemotherapy with two courses of postorchiectomy
JEB is sufficient to control as one of the treatment options.
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